JCR Pharmaceuticals Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Toru Ashida
- Full Time Employees
- 934
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 3-19 Kasuga-cho Ashiya Japan 659-0021
- IPO Date
- Jan 29, 2021
- Website
- jcrpharm.co.jp
- Similar Companies
- Business
- JCR Pharmaceuticals Co., Ltd. develops, manufactures, and commercializes biopharmaceuticals and regenerative medicines focused on rare diseases, lysosomal storage disorders, growth deficiencies, renal anemia, and graft-versus-host disease. The company offers GROWJECT for growth hormone deficiency and short stature; IZCARGO for mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion [JCR] for Fabry disease; TEMCELL HS Inj. for acute graft-versus-host disease; Epoetin Alfa BS Injection JCR and Darbepoetin Alfa BS Injection JCR for renal anemia. Founded in September 1975 and headquartered in Ashiya, Hyogo, Japan, JCR Pharmaceuticals operates primarily in Japan with subsidiaries and facilities in the United States, Brazil, the Netherlands, Luxembourg, and Switzerland. In recent developments, the company entered a licensing agreement with Alexion Pharmaceuticals in July 2025 for proprietary JUST-AAV capsids in genomic medicines, potentially worth up to $825 million; partnered with Menagen in October 2025 to commercialize Agalsidase Beta across nine MENAT markets; collaborated with Acumen Pharmaceuticals in July 2025 on an Alzheimer's therapeutic candidate; and implemented organizational changes effective October 1, 2025, including establishing a Japan Development Unit and reorganizing its Quality Assurance and Research divisions to strengthen domestic and global operations. JCR Pharmaceuticals lists on the Tokyo Stock Exchange Prime Market under ticker 4552 and trades over-the-counter as JCRRF.
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026
JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease
JCR Pharmaceuticals Co., Ltd. (OTCMKTS:JCRRF) Short Interest Update
JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology
JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives
JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025
JCR Pharmaceuticals Selected for Japan's Regenerative Medicine CDMO Subsidy Program
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website